FOOD AND DRUG ADMINISTRATION (FDA)

Office of the Commissioner (OC)

Pediatric Advisory Committee (PAC) September 17, 2021

FINAL MEETING AGENDA

The committee will discuss the pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act of 2003 (Pub. L. 108-155). The PAC will meet to discuss FLOURISH Pediatric Esophageal Atresia Device (HDE).

10:00 a.m. Call to Order and Introduction of Committee Kelly Wade, MD

Chairperson, PAC

Conflict of Interest Statement Marieann Brill, MBA, RAC, MT(ASCP)

Designated Federal Officer, PAC
Office of Pediatric Therapeutics (OPT)

Office of Clinical Policy and Programs (OCPP) Office of the Commissioner (OC), FDA

FDA Opening Remarks Dionna Green, MD

Director (Acting) OPT, OCPP, OC, FDA

10:30 a.m. FDA Presentation

Center for Devices and Radiological Health (CDRH) Annual Update of Post-Market Humanitarian Device Exemption (HDE) Review

• FLOURISH Pediatric Esophageal Atresia Device (HDE)

Lauren J. Min, PhD

Epidemiologist

DHT3A: Division of Gastroenterology, Renal, Endoscopy, Transplant and Obesity Devices OHT3: Office of Reproductive, Gastro-Renal, Urological, General Hospital Devices & Human

Factors

Office of Product Evaluation and Quality

(OPEQ) CDRH, FDA

Jian Connell, DNP, MSN, CPN

Consumer Safety Officer/Senior MDR Analyst DHT3A, OHT3, OPEQ, CDRH, FDA

11:00 a.m. Sponsor Presentation

• FLOURISH Pediatric Esophageal Atresia Device

(HDE)

Ted Heise, PhD, RAC

VP Regulatory & Clinical Services

MED Institute, Inc.

Clarifying Questions

11:30 a.m. **OPEN PUBLIC HEARING**

FOOD AND DRUG ADMINISTRATION (FDA)Office of the Commissioner

Pediatric Advisory Committee (PAC) September 17, 2021

FINAL MEETING AGENDA (cont.)

Clarifying Questions cont'd 11:32 a.m.

12:30 p.m. LUNCH

1:00 p.m. Committee Discussion and Vote

3:00 p.m. ADJOURNMENT Kelly Wade, MD

Chairperson, PAC